Mauro Di Matteo
Overview
Explore the profile of Mauro Di Matteo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
64
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maccallini C, Di Matteo M, Gallorini M, Montagnani M, Graziani V, Ammazzalorso A, et al.
Eur J Med Chem
. 2018 Apr;
152:53-64.
PMID: 29689474
In mammalian cells, aberrant iNOS induction may have detrimental consequences, and seems to be involved in the proliferation and progression of different tumors, such as malignant gliomas. Therefore, selective inhibition...
2.
Indazole, Pyrazole, and Oxazole Derivatives Targeting Nitric Oxide Synthases and Carbonic Anhydrases
Maccallini C, Di Matteo M, Vullo D, Ammazzalorso A, Carradori S, De Filippis B, et al.
ChemMedChem
. 2016 Jul;
11(16):1695-9.
PMID: 27377568
Nitric oxide (NO) is an essential endogenous mediator with a physiological role in the central nervous system as neurotransmitter and neuromodulator. A growing number of studies have demonstrated that abnormal...
3.
Di Matteo M, Ammazzalorso A, Andreoli F, Caffa I, De Filippis B, Fantacuzzi M, et al.
Bioorg Med Chem Lett
. 2016 May;
26(13):3192-3194.
PMID: 27161804
The most frequently used treatment for hormone receptor positive breast cancer in post-menopausal women are aromatase inhibitors. In order to develop new aromatase inhibitors, we designed and synthesized new imidazolylmethylpiperidine...
4.
Fantacuzzi M, Maccallini C, Di Matteo M, Ammazzalorso A, Bruno I, De Filippis B, et al.
J Pharm Biomed Anal
. 2015 Dec;
120:419-24.
PMID: 26689740
Nitric Oxide Synthase (NOS) inhibitors could play a powerful role in inflammatory and neurodegenerative diseases. In this work, novel acetamidine derivatives of NOS were synthesized and the inhibitor activity was...
5.
Maccallini C, Montagnani M, Paciotti R, Ammazzalorso A, De Filippis B, Di Matteo M, et al.
ACS Med Chem Lett
. 2015 Jun;
6(6):635-40.
PMID: 26101565
N-[(3-Aminomethyl)benzyl]acetamidine derivatives were synthesized and in vitro evaluated as inhibitors of the inducible isoform of nitric oxide synthase (iNOS). Because of the high potency of action and the excellent selectivity...
6.
Maccallini C, Di Matteo M, Ammazzalorso A, DAngelo A, De Filippis B, Di Silvestre S, et al.
J Sep Sci
. 2014 Apr;
37(12):1380-5.
PMID: 24687974
Nitric oxide synthase (NOS) inhibitors are potential drug candidates due to the critical role of an excessive production of nitric oxide in a range of diseases. At present, the radiometric...
7.
Giampietro L, DAngelo A, Giancristofaro A, Ammazzalorso A, De Filippis B, Di Matteo M, et al.
Med Chem
. 2013 Feb;
10(1):59-65.
PMID: 23432317
In an effort to develop safe and efficacious compounds for the treatment of metabolic disorders, new compounds based on a combination of clofibric acid, the active metabolite of clofibrate, and...
8.
Ammazzalorso A, DAngelo A, Giancristofaro A, De Filippis B, Di Matteo M, Fantacuzzi M, et al.
Eur J Med Chem
. 2012 Nov;
58:317-22.
PMID: 23137448
The identification of novel PPAR ligands represents an attractive research to fully understand the complex biological pathways regulated by these receptors. Selective PPAR modulators, inverse agonists and antagonists of three...